AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26649337 — intervention group
Group type: COMPARATOR
Intervention: Contrast CT/MRI and biopsy (reference methods)
Number of subjects: 1153
Study 26649807 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab combined with docetaxel (weekly cetuximab: first infusion 400 mg/m², then 250 mg/m²; docetaxel: 100 mg/m² every 3 weeks)
Number of subjects: 35
Study 26649807 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab combined with docetaxel
Number of subjects: 35
Study 26650227 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 847325 (Schedule A, 2 weeks on, 1 week off, starting at 6 mg, MTD 120 mg/day)
Number of subjects: 69
Study 26650227 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 847325 (Schedule B, three periods of 5 days on, 2 days off, MTD 150 mg/day)
Number of subjects: 69
Study 26651157 — intervention group
Group type: EXPERIMENTAL
Intervention: Tympanometry (type A and C1 tympanograms with tympanometric peak pressure >-200 daPa)
Number of subjects: 281
Study 26651157 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectral gradient acoustic reflectometry (SG-AR level 1 result >95°)
Number of subjects: 281
Study 26652141 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese Cardiac Surgery Registry (CCSR)
Number of subjects: 46303
Study 26652184 — intervention group
Group type: EXPERIMENTAL
Intervention: Dendritic cell vaccination combined with low-dose cyclophosphamide
Number of subjects: 10
Study 26652184 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cyclophosphamide
Number of subjects: 10
Study 26653566 — intervention group
Group type: EXPERIMENTAL
Intervention: ESPEN formula using body weight (BW)
Number of subjects: 85
Study 26653566 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive equations including minute ventilation and body temperature
Number of subjects: 85
Study 26653566 — intervention group
Group type: EXPERIMENTAL
Intervention: Measured body weight (BW)
Number of subjects: 85
Study 26653680 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with prior myocardial iron overload (n=19, 63.3%)
Number of subjects: 30
Study 26653680 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with prior myocardial iron overload
Number of subjects: 30
Study 26653680 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without iron overload
Number of subjects: 30
Study 26653680 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of ECV with lowest historical T2*
Number of subjects: 30
Study 26653680 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of ECV with left ventricular ejection fraction
Number of subjects: 30
Study 26653680 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of ECV with global longitudinal strain
Number of subjects: 30
Study 26653754 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid substitution therapy
Number of subjects: 2500
Study 26654128 — intervention group
Group type: EXPERIMENTAL
Intervention: Hippocampal sparing during whole brain radiotherapy (HS-WBRT)
Number of subjects: 40
Study 26654474 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based psychotherapy (EBP) offered for PTSD
Number of subjects: 324
Study 26654630 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 516
Study 26654630 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma exchange/plasma infusion
Number of subjects: 516
Study 26654630 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysis
Number of subjects: 516
Study 26654630 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidney transplant
Number of subjects: 516
Study 26654630 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of aHUS
Number of subjects: 516
Study 26654720 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnant women with a lifetime diagnosis of schizophrenia, bipolar disorder, major depressive disorder
Number of subjects: 0
Study 26654720 — intervention group
Group type: COMPARATOR
Intervention: Non-psychiatric control group
Number of subjects: 0
Study 26654720 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver-infant interaction
Number of subjects: 0
Study 26654720 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal caregiver representation
Number of subjects: 0
Study 26654720 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress
Number of subjects: 0
Study 26655841 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 or 2 intranasal doses of 10(7.0) fluorescent focus units of A/Anhui/1/2013 pLAIV (younger subjects)
Number of subjects: 49
Study 26655841 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of A/Anhui/1/2013 pLAIV (older subjects)
Number of subjects: 49
Study 26655841 — intervention group
Group type: COMPARATOR
Intervention: Single 30-µg dose of unadjuvanted, antigenically matched A/Shanghai2/2013(H7N9) pandemic inactivated influenza vaccine (pIIV)
Number of subjects: 49
Study 26655846 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-03446962 (10 mg/kg, recommended phase II dose 7 mg/kg)
Number of subjects: 44
Study 26655846 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-03446962 (0.5 to 15 mg/kg)
Number of subjects: 44
Study 26655846 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-03446962
Number of subjects: 44
Study 26655919 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarcopenia diagnosed by ultrasound measurement of rectus femoris cross-sectional area
Number of subjects: 102
Study 26655919 — intervention group
Group type: EXPERIMENTAL
Intervention: Frailty diagnosed by the Frailty Index Questionnaire
Number of subjects: 102
Study 26655919 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarcopenia and frailty models
Number of subjects: 102
Study 26655919 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarcopenia and frailty
Number of subjects: 102
Study 26656011 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual health assessments including questionnaire, physical examination, ECG, blood and urine analysis.
Number of subjects: 32404
Study 26656277 — intervention group
Group type: EXPERIMENTAL
Intervention: QLT091001 (40 mg/m2/day for 7 days)
Number of subjects: 18
Study 26656373 — intervention group
Group type: EXPERIMENTAL
Intervention: Shapiro score
Number of subjects: 1083
Study 26656373 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT)
Number of subjects: 1083
Study 26656373 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophil-lymphocyte count ratio (NLCR)
Number of subjects: 1083
Study 26656373 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Shapiro score with PCT levels
Number of subjects: 1083
Study 26656373 — intervention group
Group type: EXPERIMENTAL
Intervention: Shapiro score ≥4 or PCT > 0.1 μg/L
Number of subjects: 1083
Study 26656373 — intervention group
Group type: EXPERIMENTAL
Intervention: Shapiro score ≥3 or PCT >0.25 μg/L
Number of subjects: 1083
Study 26657810 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT) for 6 months
Number of subjects: 20
Study 26658492 — intervention group
Group type: EXPERIMENTAL
Intervention: u-healthcare group
Number of subjects: 70
Study 26658492 — intervention group
Group type: COMPARATOR
Intervention: standard care group
Number of subjects: 70
Study 26658889 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line pazopanib
Number of subjects: 278
Study 26659089 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (R)
Number of subjects: 0
Study 26659089 — intervention group
Group type: EXPERIMENTAL
Intervention: Obinutuzumab (GA101)
Number of subjects: 0
Study 26659089 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphokine-activated killer (LAK) cells
Number of subjects: 0
Study 26659089 — intervention group
Group type: EXPERIMENTAL
Intervention: LAK cells
Number of subjects: 0
Study 26659107 — intervention group
Group type: EXPERIMENTAL
Intervention: Data collected from the international PCD registry
Number of subjects: 201
Study 26659347 — intervention group
Group type: EXPERIMENTAL
Intervention: (68)Ga-PSMA-11
Number of subjects: 7
Study 26659347 — intervention group
Group type: EXPERIMENTAL
Intervention: (68)Ga-RM2
Number of subjects: 7
Study 26659347 — intervention group
Group type: EXPERIMENTAL
Intervention: (68)Ga-PSMA-11 and (68)Ga-RM2
Number of subjects: 7
Study 26659569 — intervention group
Group type: EXPERIMENTAL
Intervention: rVSV-ZEBOV vaccine
Number of subjects: 0
Study 26660428 — intervention group
Group type: EXPERIMENTAL
Intervention: CPX-351
Number of subjects: 0
Study 26660428 — intervention group
Group type: EXPERIMENTAL
Intervention: SGN-CD33A
Number of subjects: 0
Study 26662175 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective excessive daytime sleepiness (EDS) assessed by the Epworth Sleep Questionnaire (ESS) with a mean score of 5.6 ± 3.5.
Number of subjects: 232
Study 26662175 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis of RHV and LHV with ESS scores.
Number of subjects: 232
Study 26662175 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple regression analysis including age, gender, SDB severity, and hypoxia.
Number of subjects: 232
Study 26663235 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone treatment
Number of subjects: 0
Study 26663235 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 26663671 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic Stimulation Mode (AutoStim) of the Model 106 Vagus Nerve Stimulation (VNS) Therapy System
Number of subjects: 20
Study 26663671 — intervention group
Group type: EXPERIMENTAL
Intervention: VNS Normal and Magnet Modes stimulation
Number of subjects: 20
Study 26663671 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life and seizure severity scores
Number of subjects: 20
Study 26663671 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 20
Study 26663686 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacral neuromodulation (SNM)
Number of subjects: 16
Study 26663719 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 40 mg/m² for Category 1 patients
Number of subjects: 3
Study 26663719 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 30 mg/m² for Category 2 patients
Number of subjects: 3
Study 26663719 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 20 mg/m² for Category 3 patients
Number of subjects: 3
Study 26663719 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel for all categories
Number of subjects: 3
Study 26663719 — intervention group
Group type: COMPARATOR
Intervention: Comparison with Child-Pugh and NCI Organ Dysfunction Working Group systems
Number of subjects: 3
Study 26666244 — intervention group
Group type: EXPERIMENTAL
Intervention: Selumetinib 75 mg p.o. BID and cetuximab 250 mg/m(2) weekly following a 400 mg/m(2) load
Number of subjects: 33
Study 26666244 — intervention group
Group type: EXPERIMENTAL
Intervention: Selumetinib and cetuximab combination
Number of subjects: 33
Study 26666256 — intervention group
Group type: EXPERIMENTAL
Intervention: New and more effective diagnostic procedures and targeted therapies against ACC
Number of subjects: 0
Study 26666313 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI decrease
Number of subjects: 474
Study 26666313 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI increase
Number of subjects: 474
Study 26666313 — intervention group
Group type: COMPARATOR
Intervention: Minimal increase or decrease in BMI
Number of subjects: 474
Study 26666380 — intervention group
Group type: EXPERIMENTAL
Intervention: 123I-mIBG imaging
Number of subjects: 777
Study 26666380 — intervention group
Group type: COMPARATOR
Intervention: ICD implantation
Number of subjects: 777
Study 26666380 — intervention group
Group type: EXPERIMENTAL
Intervention: H/M ratio from 123I-mIBG results
Number of subjects: 777
Study 26666380 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP levels
Number of subjects: 777
Study 26666380 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular ejection fraction
Number of subjects: 777
Study 26666942 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (six-dose regimen)
Number of subjects: 60
Study 26666998 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab alone
Number of subjects: 22
Study 26666998 — intervention group
Group type: COMPARATOR
Intervention: BP pre-treated group
Number of subjects: 22
Study 26667027 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating DEHP metabolites exposure during PICU stay
Number of subjects: 449
Study 26667027 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation cohort of DEHP metabolites exposure
Number of subjects: 449
Study 26667027 — intervention group
Group type: COMPARATOR
Intervention: Healthy children
Number of subjects: 449
Study 26667382 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 weeks of varenicline in combination with smoking cessation counseling
Number of subjects: 448
Study 26668134 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide plus low-dose dexamethasone (LenDex)
Number of subjects: 31
Study 26668712 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose 13-valent pneumococcal conjugate vaccine (PCV13)
Number of subjects: 72
Study 26669474 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients' self-reports during SBT
Number of subjects: 100
Study 26669474 — intervention group
Group type: COMPARATOR
Intervention: Nurses' and physicians' assessments during SBT
Number of subjects: 100
Study 26669474 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients' perception of feeling secure and improvement of respiratory function
Number of subjects: 100
Study 26669474 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective assessments of respiratory function
Number of subjects: 100
Study 26669474 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathlessness during SBT and extubation outcome
Number of subjects: 100
Study 26669916 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA) plus Methotrexate (MTX)
Number of subjects: 1455
Study 26669916 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab (ADA) monotherapy
Number of subjects: 1455
Study 26670056 — intervention group
Group type: EXPERIMENTAL
Intervention: HeartMate 3 left ventricular assist system (LVAS)
Number of subjects: 50
Study 26670070 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 0
Study 26670070 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 26670307 — intervention group
Group type: EXPERIMENTAL
Intervention: Colestilan (6-15 g/day)
Number of subjects: 116
Study 26670466 — intervention group
Group type: EXPERIMENTAL
Intervention: rindopepimut plus bevacizumab
Number of subjects: 0
Study 26670630 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-dose photodynamic therapy (PDT)
Number of subjects: 59
Study 26670630 — intervention group
Group type: EXPERIMENTAL
Intervention: Second PDT treatment
Number of subjects: 59
Study 26670630 — intervention group
Group type: EXPERIMENTAL
Intervention: High-density subthreshold diode micropulse laser (HSML) therapy
Number of subjects: 59
Study 26670630 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment strategy (PDT + HSML)
Number of subjects: 59
Study 26670630 — intervention group
Group type: EXPERIMENTAL
Intervention: First half-dose PDT treatment
Number of subjects: 59
Study 26670913 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-based STI/HIV prevention intervention
Number of subjects: 450
Study 26670913 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussion of risks with potentially exposed partners
Number of subjects: 450
Study 26671110 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinoblastoma patients (TRb cohort)
Number of subjects: 80
Study 26671110 — intervention group
Group type: COMPARATOR
Intervention: Retinoblastoma patients (non-TRb cohort)
Number of subjects: 80
Study 26671110 — intervention group
Group type: COMPARATOR
Intervention: Age-matched controls
Number of subjects: 80
Study 26672022 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital imaging with ROP examination at discharge
Number of subjects: 650
Study 26672022 — intervention group
Group type: COMPARATOR
Intervention: ROP examination-only strategy
Number of subjects: 650
Study 26672094 — intervention group
Group type: EXPERIMENTAL
Intervention: 75-g oral glucose tolerance test
Number of subjects: 20
Study 26672094 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoglycemic intravenous glucose infusion
Number of subjects: 20
Study 26672094 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 20
Study 26672496 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary restriction of propiogenic amino acids and carnitine supplementation
Number of subjects: 0
Study 26672496 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver transplantation
Number of subjects: 0
Study 26672609 — intervention group
Group type: EXPERIMENTAL
Intervention: Tooth loss level (no teeth)
Number of subjects: 15456
Study 26672609 — intervention group
Group type: EXPERIMENTAL
Intervention: Tooth loss level (increase in level)
Number of subjects: 15456
Study 26672987 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid supplementation (1.9 g/d EPA and 1.5 g/d DHA for six weeks)
Number of subjects: 12
Study 26672987 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid supplementation
Number of subjects: 12
Study 26673413 — intervention group
Group type: EXPERIMENTAL
Intervention: AmpliSeq
Number of subjects: 2
Study 26673787 — intervention group
Group type: EXPERIMENTAL
Intervention: Horror movie
Number of subjects: 24
Study 26673787 — intervention group
Group type: COMPARATOR
Intervention: Educational movie
Number of subjects: 24
Study 26674132 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination immunotherapy trial utilizing MEDI4736 and MEDI0680
Number of subjects: 1
Study 26674498 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week exercise programme with a personal trainer
Number of subjects: 0
Study 26674520 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg simvastatin daily for one year
Number of subjects: 250
Study 26674520 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study 26674520 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 250
Study 26674763 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled phytoene diet (1-5 mg/d) for 42 days, with 3.2 mg (13)C-phytoene consumed on day 14.
Number of subjects: 4
Study 26675348 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human IL-7 (rhIL-7) administered as 3 subcutaneous doses per week.
Number of subjects: 0
Study 26675348 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection site reactions and hypersensitivity reaction to IL-7.
Number of subjects: 0
Study 26675348 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 26675764 — intervention group
Group type: EXPERIMENTAL
Intervention: Doubly labeled water (DLW) method for measuring total energy expenditure (TEE) in SBS patients.
Number of subjects: 22
Study 26675764 — intervention group
Group type: COMPARATOR
Intervention: Doubly labeled water (DLW) method for measuring total energy expenditure (TEE) in non-SBS controls.
Number of subjects: 22
Study 26675764 — intervention group
Group type: COMPARATOR
Intervention: Comparison of measured TEE between SBS and non-SBS groups.
Number of subjects: 22
Study 26675764 — intervention group
Group type: COMPARATOR
Intervention: Predicted TEE using the Escott-Stump equation for both groups.
Number of subjects: 22
Study 26675764 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect calorimetry for measuring resting energy expenditure.
Number of subjects: 22
Study 26675775 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 16
Study 26675779 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers taking vitamin D supplements
Number of subjects: 107
Study 26675779 — intervention group
Group type: EXPERIMENTAL
Intervention: Foremilk
Number of subjects: 107
Study 26675779 — intervention group
Group type: EXPERIMENTAL
Intervention: Hindmilk
Number of subjects: 107
Study 26675779 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant daily intake through breast milk of vitamin D
Number of subjects: 107
Study 26675779 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk vitamin D supply
Number of subjects: 107
Study 26676711 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonoperative management (24 hours inpatient observation with IV antibiotics, followed by 10 days of oral antibiotics)
Number of subjects: 102
Study 26676711 — intervention group
Group type: COMPARATOR
Intervention: Surgery (urgent appendectomy)
Number of subjects: 102
Study 26676711 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonoperative management
Number of subjects: 102
Study 26676711 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 102
Study 26678502 — intervention group
Group type: COMPARATOR
Intervention: <3 h/day television viewing
Number of subjects: 165087
Study 26678502 — intervention group
Group type: EXPERIMENTAL
Intervention: 5+ h/day television viewing
Number of subjects: 165087
Study 26678502 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased television viewing from 5+ h/day to 3-4 h/day
Number of subjects: 165087
Study 26678502 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased television viewing to <3 h/day
Number of subjects: 165087
Study 26678502 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased television viewing to 3-4 h/day
Number of subjects: 165087
Study 26678502 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased television viewing to 5+ h/day
Number of subjects: 165087
Study 26678502 — intervention group
Group type: EXPERIMENTAL
Intervention: Consistently active and watched <3 h/day of television
Number of subjects: 165087
Study 26678639 — intervention group
Group type: EXPERIMENTAL
Intervention: N-terminal-pro-B-type natriuretic peptide (NT-proBNP)
Number of subjects: 5592
Study 26678639 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac troponin T (TnT)
Number of subjects: 5592
Study 26678639 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in NT-proBNP
Number of subjects: 5592
Study 26678646 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombotic therapy (varied by physician discretion)
Number of subjects: 2500
Study 26678657 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic testing and histopathological techniques
Number of subjects: 1
Study 26678660 — intervention group
Group type: EXPERIMENTAL
Intervention: Volumetric radiosurgery (VRS) with 47.5 Gy in 5 fractions
Number of subjects: 60